Clinical-stage biotech
Appears in 1 story
Target of the acquisition
Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, about $2.8 billion, with up to $1 billion more if two drugs hit development targets. The purchase pulls one of the world's largest drugmakers into psychedelic medicine.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
